Paediatric cardio-oncology: Epidemiology, screening, prevention, and treatment

Eric J. Chow, Kasey J. Leger, Neel S. Bhatt, Daniel A. Mulrooney, Colin J. Ross, Sanjeev Aggarwal, Neha Bansal, Matthew J. Ehrhardt, Saro H. Armenian, Jessica M. Scott, Borah Hong

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

With 5-year survival of children with cancer exceeding 80% in developed countries, premature cardiovascular disease is now a major cause of early morbidity and mortality. In addition to the acute and chronic cardiotoxic effects of anthracyclines, related chemotherapeutics, and radiation, a growing number of new molecular targeted agents may also have detrimental effects on the cardiovascular system. Survivors of childhood cancer also may have earlier development of conventional cardiovascular risk factors such as hypertension, dyslipidaemia, and diabetes, which further increase their risk of serious cardiovascular disease. This review will examine the epidemiology of acute and chronic cardiotoxicity relevant to paediatric cancer patients, including genetic risk factors. We will also provide an overview of current screening recommendations, including the evidence regarding both imaging (e.g. echocardiography and magnetic resonance imaging) and blood-based biomarkers. Various primary and secondary prevention strategies will also be discussed, primarily in relation to anthracycline-related cardiomyopathy. Finally, we review the available evidence related to the management of systolic and diastolic dysfunction in paediatric cancer patients and childhood cancer survivors.

Original languageEnglish (US)
Pages (from-to)922-934
Number of pages13
JournalCardiovascular research
Volume115
Issue number5
DOIs
StatePublished - Apr 15 2019

Fingerprint

Epidemiology
Pediatrics
Anthracyclines
Neoplasms
Survivors
Cardiovascular Diseases
Therapeutics
Primary Prevention
Dyslipidemias
Cardiovascular System
Secondary Prevention
Cardiomyopathies
Developed Countries
Echocardiography
Biomarkers
Magnetic Resonance Imaging
Radiation
Hypertension
Morbidity
Survival

Keywords

  • Anthracycline
  • Cardio-oncology
  • Cardiomyopathy
  • Paediatric
  • Prevention
  • Survivorship

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Chow, E. J., Leger, K. J., Bhatt, N. S., Mulrooney, D. A., Ross, C. J., Aggarwal, S., ... Hong, B. (2019). Paediatric cardio-oncology: Epidemiology, screening, prevention, and treatment. Cardiovascular research, 115(5), 922-934. https://doi.org/10.1093/cvr/cvz031

Paediatric cardio-oncology : Epidemiology, screening, prevention, and treatment. / Chow, Eric J.; Leger, Kasey J.; Bhatt, Neel S.; Mulrooney, Daniel A.; Ross, Colin J.; Aggarwal, Sanjeev; Bansal, Neha; Ehrhardt, Matthew J.; Armenian, Saro H.; Scott, Jessica M.; Hong, Borah.

In: Cardiovascular research, Vol. 115, No. 5, 15.04.2019, p. 922-934.

Research output: Contribution to journalReview article

Chow, EJ, Leger, KJ, Bhatt, NS, Mulrooney, DA, Ross, CJ, Aggarwal, S, Bansal, N, Ehrhardt, MJ, Armenian, SH, Scott, JM & Hong, B 2019, 'Paediatric cardio-oncology: Epidemiology, screening, prevention, and treatment', Cardiovascular research, vol. 115, no. 5, pp. 922-934. https://doi.org/10.1093/cvr/cvz031
Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ, Aggarwal S et al. Paediatric cardio-oncology: Epidemiology, screening, prevention, and treatment. Cardiovascular research. 2019 Apr 15;115(5):922-934. https://doi.org/10.1093/cvr/cvz031
Chow, Eric J. ; Leger, Kasey J. ; Bhatt, Neel S. ; Mulrooney, Daniel A. ; Ross, Colin J. ; Aggarwal, Sanjeev ; Bansal, Neha ; Ehrhardt, Matthew J. ; Armenian, Saro H. ; Scott, Jessica M. ; Hong, Borah. / Paediatric cardio-oncology : Epidemiology, screening, prevention, and treatment. In: Cardiovascular research. 2019 ; Vol. 115, No. 5. pp. 922-934.
@article{080c175521aa4a18a3b0de8f59852d09,
title = "Paediatric cardio-oncology: Epidemiology, screening, prevention, and treatment",
abstract = "With 5-year survival of children with cancer exceeding 80{\%} in developed countries, premature cardiovascular disease is now a major cause of early morbidity and mortality. In addition to the acute and chronic cardiotoxic effects of anthracyclines, related chemotherapeutics, and radiation, a growing number of new molecular targeted agents may also have detrimental effects on the cardiovascular system. Survivors of childhood cancer also may have earlier development of conventional cardiovascular risk factors such as hypertension, dyslipidaemia, and diabetes, which further increase their risk of serious cardiovascular disease. This review will examine the epidemiology of acute and chronic cardiotoxicity relevant to paediatric cancer patients, including genetic risk factors. We will also provide an overview of current screening recommendations, including the evidence regarding both imaging (e.g. echocardiography and magnetic resonance imaging) and blood-based biomarkers. Various primary and secondary prevention strategies will also be discussed, primarily in relation to anthracycline-related cardiomyopathy. Finally, we review the available evidence related to the management of systolic and diastolic dysfunction in paediatric cancer patients and childhood cancer survivors.",
keywords = "Anthracycline, Cardio-oncology, Cardiomyopathy, Paediatric, Prevention, Survivorship",
author = "Chow, {Eric J.} and Leger, {Kasey J.} and Bhatt, {Neel S.} and Mulrooney, {Daniel A.} and Ross, {Colin J.} and Sanjeev Aggarwal and Neha Bansal and Ehrhardt, {Matthew J.} and Armenian, {Saro H.} and Scott, {Jessica M.} and Borah Hong",
year = "2019",
month = "4",
day = "15",
doi = "10.1093/cvr/cvz031",
language = "English (US)",
volume = "115",
pages = "922--934",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Paediatric cardio-oncology

T2 - Epidemiology, screening, prevention, and treatment

AU - Chow, Eric J.

AU - Leger, Kasey J.

AU - Bhatt, Neel S.

AU - Mulrooney, Daniel A.

AU - Ross, Colin J.

AU - Aggarwal, Sanjeev

AU - Bansal, Neha

AU - Ehrhardt, Matthew J.

AU - Armenian, Saro H.

AU - Scott, Jessica M.

AU - Hong, Borah

PY - 2019/4/15

Y1 - 2019/4/15

N2 - With 5-year survival of children with cancer exceeding 80% in developed countries, premature cardiovascular disease is now a major cause of early morbidity and mortality. In addition to the acute and chronic cardiotoxic effects of anthracyclines, related chemotherapeutics, and radiation, a growing number of new molecular targeted agents may also have detrimental effects on the cardiovascular system. Survivors of childhood cancer also may have earlier development of conventional cardiovascular risk factors such as hypertension, dyslipidaemia, and diabetes, which further increase their risk of serious cardiovascular disease. This review will examine the epidemiology of acute and chronic cardiotoxicity relevant to paediatric cancer patients, including genetic risk factors. We will also provide an overview of current screening recommendations, including the evidence regarding both imaging (e.g. echocardiography and magnetic resonance imaging) and blood-based biomarkers. Various primary and secondary prevention strategies will also be discussed, primarily in relation to anthracycline-related cardiomyopathy. Finally, we review the available evidence related to the management of systolic and diastolic dysfunction in paediatric cancer patients and childhood cancer survivors.

AB - With 5-year survival of children with cancer exceeding 80% in developed countries, premature cardiovascular disease is now a major cause of early morbidity and mortality. In addition to the acute and chronic cardiotoxic effects of anthracyclines, related chemotherapeutics, and radiation, a growing number of new molecular targeted agents may also have detrimental effects on the cardiovascular system. Survivors of childhood cancer also may have earlier development of conventional cardiovascular risk factors such as hypertension, dyslipidaemia, and diabetes, which further increase their risk of serious cardiovascular disease. This review will examine the epidemiology of acute and chronic cardiotoxicity relevant to paediatric cancer patients, including genetic risk factors. We will also provide an overview of current screening recommendations, including the evidence regarding both imaging (e.g. echocardiography and magnetic resonance imaging) and blood-based biomarkers. Various primary and secondary prevention strategies will also be discussed, primarily in relation to anthracycline-related cardiomyopathy. Finally, we review the available evidence related to the management of systolic and diastolic dysfunction in paediatric cancer patients and childhood cancer survivors.

KW - Anthracycline

KW - Cardio-oncology

KW - Cardiomyopathy

KW - Paediatric

KW - Prevention

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=85064490814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064490814&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvz031

DO - 10.1093/cvr/cvz031

M3 - Review article

C2 - 30768157

AN - SCOPUS:85064490814

VL - 115

SP - 922

EP - 934

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 5

ER -